Inihahanda pa ang salin na ito. Samantala, pansamantala naming ipinapakita ang orihinal na bersiyong Ingles.
Mga startup · 10/27/20261 min read
Orphan Therapeutics Accelerator In-Licenses Investigational Gene Therapy Program for Ornithine Transcarbamylase Deficiency from UCL Ventures and Children's Medical Research Institute
Lokal na awtomatikong pagsasalin · Orihinal na wika ng pinagmulan
Buod
OTXL-101, a promising therapy in development for a severe, rare pediatric metabolic condition, becomes the first pipeline program to be in-licensed by Orphan Therapeutics Accelerator (OTXL) CAMBRIDGE, Mass., Oct. 27,…
Orihinal na wika ng pinagmulan: PR Newswire UK — News ReleasesBuksan ang orihinal na pahayag →